CN106511324A - Compound mannitol injection - Google Patents
Compound mannitol injection Download PDFInfo
- Publication number
- CN106511324A CN106511324A CN201611054765.9A CN201611054765A CN106511324A CN 106511324 A CN106511324 A CN 106511324A CN 201611054765 A CN201611054765 A CN 201611054765A CN 106511324 A CN106511324 A CN 106511324A
- Authority
- CN
- China
- Prior art keywords
- mannitol
- injection
- formula
- sorbitol
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention discloses compound mannitol injection. The compound mannitol injection is characterized by consisting of the following formula in percentage by weight: 5-18% of mannitol, 20-2% of sorbitol, and the balance of water for injection. The invention relates to a formula of medical compound mannitol injection. The formula contains mannitol and sorbitol at the same time. The compound mannitol injection cannot separate out crystals at lower room temperature to solve the crystallization problem of mannitol injection, and is an ideal mannitol preparation convenient to clinically use and with few adverse reactions.
Description
Technical field
The present invention relates to a kind of medical field, and in particular to a kind of formula of compound formula mannitol injection liquid.The formula
Mannitol and Sorbitol is included simultaneously.The compound formula mannitol injection liquid does not have crystallization and separates out when room temperature is relatively low, solves sweet
The crystallisation problems of dew alcohol injection, are that a kind of Clinical practice is convenient, the few preferable mannitol formulations of untoward reaction.
Background technology
20% formula mannitol injection liquid is widely used in facing for neurosurgery as intracranial pressure and free radical scavenger is reduced
Bed.At present, treat cerebral edema, reduce intracranial pressure, Mannitol is first-selected, reduces intracranial pressure effect is significant, without substantially " knock-on is existing
As ".Due to 20% mannitol solution system supersaturated solution, during Clinical practice, the crystallization of formula mannitol injection liquid is to clinic
Using very big inconvenience is brought, when room temperature is less than 15 DEG C, separating out crystallization Mannitol, it is impossible to use immediately, needing will knot more
Crystalline substance dissolve after can intravenous injection, waste time and energy.In addition, some crystallizations are in invisible fine particles, in such case
Lower use can cause the adverse consequencess such as infusion reaction.
Isomerss of the Sorbitol for Mannitol, effect, purposes are similar to Mannitol, but Sorbitol part in vivo
Convert and lose hypertonic effect, effect is weak compared with Mannitol, but on the other hand, Sorbitol is bigger than Mannitol dissolubility.Therefore,
The present invention intends solving the above problems, and is made into compound formula mannitol, to reduce the crystallization of Mannitol and reduce the bad anti-of Mannitol
Should.
The content of the invention
The present invention provides a kind of medical compound formula mannitol injection liquid, its objective is for substituting existing medical Mannitol injection
Liquid, to solve (when room temperature is relatively low) the easily crystallization precipitation at low ambient temperatures of current formula mannitol injection liquid, causes infusion reaction etc.
The problem of adverse consequencess, is Clinical practice provides convenient.
For reaching above-mentioned purpose, the technical solution used in the present invention is：A kind of compound formula mannitol injection liquid, by formula as below
Composition：
5%～18% weight of Mannitol；
20%～2% weight of Sorbitol；
Water for injection surplus.
Relevant content in above-mentioned technical proposal is explained as follows：
1st, in such scheme, in the formula, preferable content range is：
10%～18% weight of Mannitol；
12.5%～2.5% weight of Sorbitol；
Water for injection surplus.
2., in such scheme, in the formula, optimum content scope is：
15%～18% weight of Mannitol；
6.25%～2.5% weight of Sorbitol；
Water for injection surplus.
3rd, mechanism of the invention
In order to solve the problems, such as crystallization of mannitol, mannitol concentration is suitably reduced, and osmotic pressure is not reduced, add same point of Mannitol
Isomer Sorbitol, because the dissolubility of Sorbitol is bigger than Mannitol, reduces mannitol concentration, increases sorbitol concentration,
To reach, osmotic pressure is constant, which reduces Mannitol crystallization separate out, solve Clinical practice inconvenience, while reduce due to
The untoward reaction that microgranule causes.
As such scheme is used, the present invention has following advantages and effect compared with prior art：
1st, advantage：(1), Clinical practice is convenient；(2) untoward reaction such as infusion reaction, are reduced.
2nd, effect：Mannitol is prepared respectively：Sorbitol (5%：18.75%；10%：12.5%；15%：6.25%；
18%：2.5%) the compound formula mannitol solution 250ml of four kinds of specifications, put 2～8 DEG C of refrigerators after 24 hours, and observation crystallization separates out feelings
Condition, as a result first three specification nodeless mesh precipitation, a kind of last specification have a small amount of crystallization.
Specific embodiment
With reference to embodiment, the invention will be further described：
Embodiment one：
(1), formula
10% weight of Mannitol；
12.5% weight of Sorbitol；
Water for injection surplus.
(2), preparation method
Routinely Mannitol production method.The conventional mannitol production method refers to 20% Mannitol note described in the prior art
Penetrate the production method of liquid.
Embodiment two：
(1), formula
15% weight of Mannitol；
6.25% weight of Sorbitol；
Water for injection surplus.
(2), preparation method
Routinely Mannitol production method.The conventional mannitol production method refers to 20% Mannitol note described in the prior art
Penetrate the production method of liquid.
Embodiment three：
(1), formula
16% weight of Mannitol；
5% weight of Sorbitol；
Water for injection surplus.
(2), preparation method
Routinely Mannitol production method, the conventional mannitol production method refer to 20% Mannitol note described in the prior art
Penetrate the production method of liquid.
Above-described embodiment technology design only to illustrate the invention and feature, its object is to allow person skilled in the art
Scholar will appreciate that present disclosure and implement according to this, can not be limited the scope of the invention with this.It is all according to the present invention
Equivalence changes or modification that spirit is made, should all be included within the scope of the present invention.
Claims (3)
1. a kind of compound formula mannitol injection liquid, it is characterised in that be made up of formula as below：
5%～18% weight of Mannitol；
20%～2% weight of Sorbitol；
Water for injection surplus.
2. compound formula mannitol injection liquid according to claim 1, it is characterised in that：Preferable content range in the formula
For：
10%～18% weight of Mannitol；
12.5%～2.5% weight of Sorbitol；
Water for injection surplus.
3. compound formula mannitol injection liquid according to claim 1, it is characterised in that：Optimum content scope in the formula
For：
15%～18% weight of Mannitol；
6.25%～2.5% weight of Sorbitol；
Water for injection surplus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611054765.9A CN106511324A (en) | 2016-11-25 | 2016-11-25 | Compound mannitol injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611054765.9A CN106511324A (en) | 2016-11-25 | 2016-11-25 | Compound mannitol injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106511324A true CN106511324A (en) | 2017-03-22 |
Family
ID=58357212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611054765.9A Withdrawn CN106511324A (en) | 2016-11-25 | 2016-11-25 | Compound mannitol injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106511324A (en) |
-
2016
- 2016-11-25 CN CN201611054765.9A patent/CN106511324A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102627688B (en) | High purity cyclic peptide compound and preparation method and application thereof | |
| WO2010117091A3 (en) | Antimycotic pharmaceutical composition | |
| CN107106577A (en) | Poultice | |
| JP4967659B2 (en) | Method for purifying L-carnitine | |
| CN106397249A (en) | High-stability LCZ696 crystallized powder and a preparing method thereof | |
| CN105001289A (en) | Eprinomectin refining method | |
| RU2016141449A (en) | SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING BIOPTERIN DERIVATIVES AND METHODS FOR USING SUCH COMPOSITIONS | |
| US8765190B2 (en) | Injectable sterile pharmaceutical composition with piperacillin sodium and tazobactam sodium as active principles | |
| CN106511324A (en) | Compound mannitol injection | |
| CN103315999A (en) | Compound amino acid composition and preparation method thereof | |
| CA2985325C (en) | Cyclic compounds for inhibition of toll-like receptor 4 | |
| CN109619109A (en) | A kind of pyraclostrobin compounds aqueous suspension agent and preparation method thereof with figured silk fabrics bacterium amine | |
| CN101961312B (en) | Lipoid acid composition for injection | |
| CN109953942A (en) | Compound formula mannitol injection liquid | |
| CN108938604A (en) | Compound formula mannitol injection liquid | |
| CN109923101A (en) | Cyclic compound | |
| MD4484C1 (en) | Crystalline form VIII of agomelatine, preparation method, use thereof and pharmaceutical composition containing the same | |
| CN103265532A (en) | Preparation method of C-type candesartan cilexetil crystal | |
| CN102652755B (en) | Mannitol sodium chloride injection and preparation method thereof | |
| RU2535049C1 (en) | Method of producing stabilised drotaverine hydrochloride substance | |
| JP2010059125A (en) | Method for crystallizing citrulline | |
| CN108467230A (en) | A kind of biology waterproof agent prescription | |
| CN102657677B (en) | Glycerin fructose sodium chloride injection | |
| CN104263255A (en) | A preparing method of an ethylhexyl alpha-cyanoacrylate adhesive | |
| RU2016119523A (en) | SMALL CRYSTALS OF 2- [3-CYANO-4- (2-METHYLPROPOXY) PHENYL] -4-METHYLTHIAZOL-5-CARBONIC ACID, THE PRODUCT OF THIN FINE GRINDING AND CONTAINING THERE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170322 |
|
| WW01 | Invention patent application withdrawn after publication |